The Drug That Could Make Chemo Optional for Lung Cancer Patients

OptiTROP-Lung06 tackled the harder population: PD-L1-negative patients, who typically need chemotherapy because immunotherapy alone doesn't cut it. This trial compared sac-TMT plus Keytruda against the current gold standard of Keytruda plus platinum-based chemo. The ADC combo met its primary endpoint, significantly improving progression-free survival over the control arm.

No new safety signals emerged. Both trials hit their primary endpoints at prespecified interim analyses.

Why This Is a Big Deal (and Why "Paradigm Shift" Isn't Hyperbole)

Leerink Partners called this "the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for NSCLC." That's Wall Street analyst-speak for: this has literally never been done before.

Platinum chemotherapy has been the backbone of lung cancer treatment for so long that it's almost hard to imagine oncology without it. But platinum comes with a laundry list of problems: kidney damage, hearing loss, severe nausea, bone marrow suppression, nerve damage. Even with the addition of immunotherapy over the past several years, about 74% of patients still see their disease progress within five years. Extending chemo beyond four to six cycles doesn't improve survival; it just piles on toxicity.

Replacing that backbone with a targeted ADC isn't just an incremental improvement. It's a structural change in how we think about treating the most common form of lung cancer.

Meanwhile, at Pfizer's House...

The timing makes this even more striking. Pfizer's ADC sigvotatug vedotin, inherited from the $43 billion Seagen acquisition, recently failed its own Phase 3 lung cancer trial. That study (in previously treated NSCLC, not first-line) couldn't beat docetaxel on overall survival.

Different target (integrin β6, not TROP2), different setting (second-line, not first-line), different comparator. But the optics are unavoidable: Pfizer spent a historic sum acquiring Seagen's ADC platform, and its lung cancer ADC stumbled. Merck's partnered ADC, developed with a much smaller Chinese biotech, just delivered the kind of result the entire field has been chasing.

Pfizer still has a first-line NSCLC trial running for sigvotatug vedotin combined with Keytruda. But Merck just set the bar considerably higher.

The Race to Own Lung Cancer's Future

Sac-TMT isn't operating in a vacuum. The ADC landscape in lung cancer is getting crowded, fast. AstraZeneca and Daiichi Sankyo have datopotamab deruxtecan (Dato-DXd), another TROP2-targeting ADC with positive Phase 3 signals in previously treated NSCLC. Trastuzumab deruxtecan (T-DXd) already has approval in HER2-selected lung cancer. And several other ADCs targeting c-MET, HER3, and other proteins are moving through late-stage trials.

But none of them have first-line, chemo-replacement data. That's what makes sac-TMT's position unique: it's not just showing that ADCs work in lung cancer, it's showing they can replace the thing oncologists have relied on for decades.

Leerink highlighted sac-TMT's "workhorse potential," suggesting it could become a backbone treatment across multiple lung cancer populations. RBC Capital Markets emphasized that the PD-L1-negative win extends the validated combo into the segment where patients have the fewest good options.

What Comes Next

A few important caveats before we declare chemotherapy dead.

First, overall survival data are still maturing. Both trials showed positive OS trends, but definitive proof that sac-TMT helps patients live longer (not just delay progression) requires more follow-up. Second, much of the clinical data comes from trials conducted primarily in China; global regulatory submissions and broader validation are still ahead. Merck has its own global Phase 3 program, TroFuse-007, in high PD-L1 NSCLC.

Third, there's the question of cost and access. ADCs are expensive, and replacing cheap generic platinum chemo with a cutting-edge biologic raises serious health economics questions that payers and regulators will scrutinize closely.

But the direction of travel is clear. As DelveInsight put it, these findings "position the ADC plus immunotherapy approach as a promising new treatment paradigm." Analysts see sac-TMT as a core asset in Merck's strategy to sustain its lung cancer dominance as Keytruda's patents eventually expire.

For patients, the promise is more direct: a treatment that targets their cancer with precision instead of poisoning everything in its path. The data say it works better, too. That's not a minor upgrade. That's a new era knocking on the door.

The Drug That Works But Can't Get Made

The FDA just rejected a liver cancer drug for the third consecutive time, and the reason has nothing to do with whether the drug actually works. Hengrui and Elevar's manufacturing woes are becoming a cautionary tale for every biotech relying on overseas factories.